Imiquimod as a dermatological therapy

Bibliography

• MILLER R: Imiquimod stimulates innate and cell mediated immunity which controls virus infections and tumors. Intl: Dermatul (2002) 41(Suppl.):3–6.
   Google Scholar
• MILLER R, GERSTER JF, OWENS ML et al.: Imiquimod applied topically: a novel immune response modifier and new class of drug. Int. j Immunopharmacul (1999) 21:1–14.
   PubMed Web of Science ®Google Scholar
• AKIRA S, TAKETA K, LAISHO T: Toll-like receptors: critical proteins linking innate and acquired immunity. Nat. Immunol. (2001) 2:675–680.
   PubMed Web of Science ®Google Scholar
• ••An overview of TLRs family.
   Google Scholar
• HEMMI H, KAISHO T, TAKEUCHI 0 et al.: Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signalling pathway.Nat. Immunol. (2002) 3:196–200.
   Google Scholar
• ••An informative animal experiment on theinteraction between imidazoquinolines and TLR7 and Myd88-dependent signalling pathway.
   Google Scholar
• HURWITZ D, PINCUS L, KUPPER T: Imiquimod, a topically applied link between innate and acquired immunity.aArch. Dermatul (2003) 139:1347–1350.
   PubMedGoogle Scholar
• ITO T, AMAKAWA R, KAISHO T et al: Interferon-alpha and interleukin-12 are induced differentially by toll-like receptor 7 ligands in human blood dendritic cell subsets. Exp. Med. (2002) 195:1507–1512.
   PubMed Web of Science ®Google Scholar
• GIBSON S, LINDH J, RITER T et al: Plasmacytoid dendritic cells produce cytokines and mature in response to the TLR7 agonists, imiquimod and resiquimod.Immund (2002) 218:74–86.
   Google Scholar
• KOUTSKY L: Epidemiology of genital human papillomavirus infections. Am. Med. (1997) 102(5a): 3–8.
   Google Scholar
• COLEMAN N, BIRLEY HDL,RENTON AM et al: Immunological events\in regressing genital warts. Am. I Clin. Pathol (1994) 102:768–774.
   PubMed Web of Science ®Google Scholar
• TYPING S, ARANY I, STANLEY M et al.: A randomized controlled, molecular study of condylomata acuminata clearance during treatment with imiquimod. j. Infect. Dis. (1998) 178:551–555.
   PubMedGoogle Scholar
• BEUTNER K, SPRUANCE S,HOUGHAM A et al.: Treatment of genital warts with an immune-response modifier (imiquimod). Am. Acad. Dermatul (1998) 38:230–239.
   Google Scholar
• EDWARDS L, FERENCZY A, LAWRENCE E et al: Self-administered topical imiquimod cream for external anogenital warts. Arch. Dermatul (1998) 134:25–30.
   PubMed Web of Science ®Google Scholar
• SCHAEN L, MERCURIO MG: Treatment of human papilloma virus in a 6-month-old infant with imiquimod 5% cream.aPediatr. Dermatul (2001) 18:450–452.
   PubMedGoogle Scholar
• HENGGE UR, ESSER S, SCHULTEWOLTER T et al.: Self-administered topical 5% imiquimod for the treatment of common warts and molluscum contagiosum. Br. Dermatul (2000) 143:1026–1031.
   PubMed Web of Science ®Google Scholar
• SKINNER RB, RAYS, TALANIN NY: Treatment of molluscum contagiosum with topical 5% imiquimod cream.\Pediatr. Deramtul (2000) 17:420–423.
   PubMed Web of Science ®Google Scholar
• GRUSSENDORF-CONEN El, JACOBS S: Efficacy of imiquimod 5% cream in the treatment of recalcitrant warts in children. Pediatr. Deramtul (2002) 19:263–266.
   PubMed Web of Science ®Google Scholar
• GILBERT J, DREHS M, WEINBERG Jet al.: Topical imiquimod for acyclovir-unresponsive herpes simplex virus 2 infection. Arch. Dermatul (2001) 137:1015–1017.
   Google Scholar
• MILLER RL, IMBERTSON LM, REITER MJ et al.: Treatment of primary herpes simplex virus infection in guinea pigs by imiquimod. Antiviral. Res. (1999) 44:31–42.
   PubMed Web of Science ®Google Scholar
• HARRISON CJ, MILLER RL, BERNSTEIN DI et al: Reduction of recurrent HSV disease using imiquimod alone or combined with a glycoprotein vaccine. Vaccine. (2001) 19:1820–1826.
   PubMed Web of Science ®Google Scholar
• SCHACKER TW, CONANT M, THOMING C et al.: Imiquimod 5-percent cream does not alter the natural history of recurrent herpes genitalis: a Phase II, randomized, double-blind, placebo-controlled study. Antimicrob. Agents. Chen-label: (2002) 46:3243–3248.
   Google Scholar
• SPRUANCE S, TYPING S, SMITH M et al.: Application of a topically applied immune response modifier, resiquimod gel, to modify the recurrence rate of recurrence genital herpes: a pilot study. Infect. Dis. (2001) 84:196–200.
   Web of Science ®Google Scholar
• MARKS R, RENNIE G, SELWWOD TS: Malignant transformation of solar keratosesto squamous cell carcinoma in the skin: a prospective study. Lancet (1988) 1:795–797.
   PubMed Web of Science ®Google Scholar
• MARKS R, JOLLEY D, LECTSAS S et al: The role of childhood exposure to sunlight in the development of solar keratoses and non-melanocytic skin cancer. Med. Aust. (1990) 152:62–66.
   PubMed Web of Science ®Google Scholar
• STOCKFLETH E, MEYER T, BENNINGHOFF B et al.: Successful treatment of actinic keratosis with imiquimod cream 5%: a report of six cases. Br. Dermatul (2001) 144:1050–1053.
   PubMed Web of Science ®Google Scholar
• STOCKFLETH E, MEYER T,BENNINGHOFF B et al.: A randomized, double-blind, vehicle-controlled study to assess 5% imiquimod cream for the treatment of multiple actinic keratoses. Arch. Dermatul (2002) 138:1498–1502.
   Google Scholar
• PERSAUD A, SHAMUELOVA E, SHERER et al: Clinical effect of imiquimod 5% cream in the treatment of actinic keratosis. Am. Acad. Dermatul (2002) 47:553–556.
   PubMedGoogle Scholar
• SALASCHE S, LEVINE N,MORRISON L et al.: Cycle therapy of actinic keratoses of the face and scalp with 5% topical imiquimod cream: an open-label trial. J. Am. Acad. Dermatul (2002) 47:571–577.
   Google Scholar
• CHEN K, YAP LM, MARK R et al: Short-course therapy with imiquimod 5% cream for solar keratoses: a randomized controlled trial. Australas. .1. Dermatul (2003) 44:250–255.
   Google Scholar
• MARKS R, STAPLES M, GILES G: Trends in non-melanocytic skin cancer treated in Australia: the second national survey. bt.j Cancer (1993) 53:585–590.
   Google Scholar
• STAPLES M, MARKS R, GILES G: Trends in the incidence of non-melanocytic skin cancer (NMSC) treated in Australia 1985-1995: are primary prevention programs staring to have an effect?. bt.j Cancer (1998) 78:144–148.
   Google Scholar
• SALASCHE S: Imiquimod 5% cream: a new treatment option for basal cell carcinoma. Int. Dermatul (2002) 41(Suppl.):16–20.
   Google Scholar
• WONG D, BISHOP GA, LOWES MA et al.: Cytokine profiles in spontaneously regressing basal cell carcinomas.Br. Dermatul (2000) 143:91–98.
   PubMed Web of Science ®Google Scholar
• UROSEVIC M, MAIER T,BENNINGHOFF B et al.: Mechanisms underlying imiquimod-induced regression of basal cell carcinoma in vivo.Arch. Dermatul (2003) 139:1325–1332.
   Google Scholar
• BEUTNER K, GEISSE J, HELMAN D et al.: Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream. j. Am. Acad. Dermatol (1999) 41:1002–1007.
   PubMed Web of Science ®Google Scholar
• MARKS R, GEBAUER K, SHUMACK S et al.: Imiquimod 5% cream in the treatment of superficial basal cell carcinoma: results of a multicentre 6-week dose-response trial. Am. Acad. Dermatol (2001) 44:807–813.
   PubMed Web of Science ®Google Scholar
• GEISSE J, RICK P, PANDYA A et al: Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: a double-blind, randomized, vehicle-controlled study. J Am. Acad. Dermatol (2002) 47:390–398.
   PubMed Web of Science ®Google Scholar
• STERRY W, RUZICKA T, HERRERA E et al.: Imiquimod 5% cream for the treatment of superficial and nodular basal cell carcinoma: randomised studies comparing low-frequency dosing with and without occlusion. Br. .1 Dermatol (2002) 147:1227–1236.
   Google Scholar
• CHEN T, MINSUE BS, ROSEN et al.: Treatment of a large superficial basal cell carcinoma with 5% imiquimod: a case report and review of the literature. Dermatol Surg. (2002) 28:344–346.
   PubMedGoogle Scholar
• GOLLNICK H, GUILLEN BARONA C, FRANK R et al.: Long-term efficacy of imiquimod 5% cream for the treatment of superficial basal cell carcinoma: a European study. Poster presentation at the 12th Congress of EADV October 15–18 (2003).
   Google Scholar
• QUIRK C, GEBAUER K,DEAMBROSIS B et al.: Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: a long-term follow-up study in Australia and New Zealand - interim 12-month follow up results. Poster presentation at the 12-h Congress of EAD V October 15–18 (2003).
   Google Scholar
• WEISBERG NK, VARGHESE M: Therapeutic response of brother and sister with xeroderma pigmentosum to imiquimod 5% cream. Dermatol Surg. (2002) 28:518–523.
   PubMedGoogle Scholar
• MICALI G, CALTABIANO R, LACARRUBBA F et al.: The use of imiquimod 5% cream for the treatment of basal cell carcinoma as observed in Gorlin's syndrome. Clin. Exp. Dermatol (In Press).
   Google Scholar
• CARO I, GEISSE J, LINDHOHM J et al.: Efficacy and safety of imiquimod 5% in the treatment of superficial basal cell carcinoma. Eur. Acad. Dermatol Venereol (2003) 17\(Suppl. 3):204.
   Google Scholar
• SHUMACK S, ROBINSON J, KOSSARD S et al.: Efficacy of topical 5% Imiquimod cream for the treatment of nodular basal cell carcinoma.Arch. Dermatol (2002) 138:1165–1171.
   Google Scholar
• MACKENZIE-WOOD A, KOSSARD S, LAUNEY J et al.: Imiquimod 5% cream in the treatment of Bowen's disease.' Am. Acad. Dermatol (2001) 44:462–470.
   Google Scholar
• CHEN K, SHUMACK S: Treatment of Bowen's disease using a cycle regime of imiquimod 5% cream. Clin. Exp. Dermatol (2003) 28(Suppl 1):10–12..
   PubMedGoogle Scholar
• THAI K, SINCLAIR R: Treatment of bowen's disease of the penis with imiquimod. .1 Am. Acad. Dermatol (2002) 46:470–471.
   PubMed Web of Science ®Google Scholar
• SCHROEDER T, SENGEMANN R: Squamous cell carcinoma in situ of the penis successfully treated with imiquimod 5% cream.' Am. Acad. Dermatol (2002) 46:545–548.
   PubMed Web of Science ®Google Scholar
• GUTZMER R, KASPARI M, VOGELBRUCH M et al: Successful treatment of anogenital Bowen's disease with the immunomodulator imiquimod, and monitoring if therapy by DNA image cytometry. Br.j Dermatol (2002) 147:160–165.
   PubMed Web of Science ®Google Scholar
• WU J, SILLER G, WHITEHEAD K: Treatment of Bowen's disease and basal cell carcinoma of the nose with imiquimod 5% cream. Australas.J. Dermatol (2003) 44:123–125.
   PubMedGoogle Scholar
• SMITH K, GERMAIN M, SKELTON H: Bowen's disease (squamous cell carcinoma in situ) in immunosuppressed patients treated with imiquimod 5% cream and a Cox Inhibitor, sulindac: potential applications for this combination of immunotherapy. Dermatol Surg. (2001) 27:143–146.
   PubMed Web of Science ®Google Scholar
• SMITH K, GERMAIN M, SKELTON H: Squamous cell carcinoma in situ (Bowen's disease) in renal transplant patients treated with 5% imiquimod and 5% 5-fluorouracil therapy. Dermatol Surg. (2001) 27:561–564.
   PubMed Web of Science ®Google Scholar
• PEHOUSHEK J, SMITH K: Imiquimod and 5% fluorouracil therapy for anal and perianal squamous cell carcinoma in situ in an HIV-1-positive man. Arch. Dermatol (2001) 137:14–16.
   PubMed Web of Science ®Google Scholar
• AHMED I, BERTH-JONES J: Imiquimod: a novel treatment for lentigo maligna. Br. .1 Dermatol (2000) 143:843–845.
   Google Scholar
• SOMMERFELD B: Successful treatment of lentigo maligna using imiquimod 5% cream - a case report. Eur. Acad. Dermatol Venereol (2002) 16 (Suppl. 1):197.
   Google Scholar
• ROEST MAB, WILKINSON JD: Lentigo maligna treated with imiquimod. I Eur: Acad. Dermatol Venereol (2002) 16\(Supp1.1):254.
   Google Scholar
• CHAPMAN MS: Histological resolution of melanoma in situ (lentigo maligna) with 5% imiquimod cream. Arch. Dermatol (2003) 139:943–944.
   PubMedGoogle Scholar
• ESPTEIN E: Extensive lentigo maligna clearing with topical imiquimod. Arch. Dermatol (2003) 139:944–945.
   PubMedGoogle Scholar
• FISHER G: Treatment of melanoma in situ on sun-damaged skin with topical5% imiquimod cream complicated by the development if invasive disease.Arch. Dermatol (2003) 139:945–947.
   PubMedGoogle Scholar
• BRYDEN AM, EVANS A, DAWE RS: A pilot investigative study of imiquimod in the treatment of lentigo maligna. Br. Dermatol (2003) 149\(Suppl. 64):42.
   Google Scholar
• DIAKOMANOLIS E,HAIDOPOULOS D, STEFANIDIS K: Treatment of high-grade vaginal intraepithelial neoplasia with imiquimod cream. N Engl. I Med. (2002) 347:374–375.
   PubMedGoogle Scholar
• PETROW W, GERDSEN R, UERLICH M et al.: Successful topical immunotherapy of bowenoid papulosis with imiquimod. Br. Dermatol (2001) 145:1022–1036.
   PubMed Web of Science ®Google Scholar
• STEINMANN A, FUNK JO, SCHLER Get al.: Topical imiquimod treatment of a cutaneous melanoma metastasis. Am. Acad. Dermatol (2000) 43:555–556.
   Google Scholar
• MARTINEZ M, SANCHEZ-CARPINTERO I, NORTH P et al: Infantile hemangioma: clinical resolution with 5% imiquimod cream. Arch. Dermatol (2002) 138:881–883.
   PubMedGoogle Scholar
• ZAMPOGNA J, FLOWERS F, ROTH W et al.: Treatment of primary limited cutaneous extramammary Paget's disease with topical imiquimod monotherapy: two case reports. Am. Acad. Dermatol (2002) 47:S229–S235.
   Google Scholar
• AGARWAL S, BERTH-JONES J: Porokeratosis of Mibelli: successful treatment with 5% imiquimod cream. Br. Dermatol (2002) 146:338–339.
   PubMedGoogle Scholar
• RINNE D, SCHOFER H: Lip papillomatosis in immunodeficiency:atherapy with imiquiamod. Br. I Dermatol(2000) 142:196–197.
   PubMed Web of Science ®Google Scholar
• BAUMANN L, HALEM M: Lip siliconegranulomatous foreign body reaction treated with Aldara (imiquimod 5%).Dermatol Stag. (2003) 29:429–432.
   PubMed Web of Science ®Google Scholar
• STOCKFLETH E, RWERT J, ARNDT C et al.: Detection of human papillomavirus and response to topical 5% imiquimod in a case of stucco keratosis. Br. J. Dermatol(2000) 143:846–850.
   PubMed Web of Science ®Google Scholar
• KUWAHARA R, NAYLOR M, SKINNER R: Treatment of granulomaannulare with topical 5% imiquimod cream. Pediatr. Dermatol (2003) 20:90–91.
   PubMedGoogle Scholar
• AREVALO I, WARD B, MILER R et al: Successful treatment of drug-resistant cutaneous leishmaniasis in human by use of imiquimod, an immunomodulator.Clin. Infect. Dis. (2002) 33: 1847-1851.
   Google Scholar
• BERMAN B, KAUFMAN J: Pilot study of the effect of postoperative imiquimod 5% cream on the recurrence rate of excised keloids. J. Am. Acad. Dermatol (2002) 47:S209–S211.
   Google Scholar
• KAIDBEY K, OWENS M, LIBERDA M et al.: Safety studies of topical imiquimod 5% cream on normal skin exposed to ultraviolet radiation. Toxicology (2002) 178:175–182.
   PubMed Web of Science ®Google Scholar